v3.26.1
Segment Reporting
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s chief operating decision makers (the “CODM function”), which are the Company’s Co-Chief Executive Officers, Mr. Duggan and Dr. Zanganeh, and Chief Operating Officer and Chief Financial Officer, Mr. Soni, utilize consolidated net loss that is reported on the unaudited condensed consolidated statement of operations and comprehensive loss to make decisions about allocating resources and assessing performance for the entire Company. The CODM function approves key operating and strategic decisions, including key decisions in clinical development and clinical operating activities, entering into significant contracts, such as revenue contracts and collaboration agreements and approves the Company’s consolidated operating budget. The CODM function views the Company’s operations and manages its business on a consolidated basis and as a single reportable operating segment. The CODM function is regularly provided with the following significant segment expenses:
Three Months Ended
June 30,		Six Months Ended
June 30,
2026202520262025
Oncology clinical trial related costs$114,339 $67,824 $204,534 $104,187 
Compensation related costs, excluding stock-based compensation27,996 16,800 54,428 32,654 
Stock-based compensation68,706 478,784 141,497 489,880 
Other expenses (1)
9,455 5,029 15,249 8,567 
Total segment expenses220,496 568,437 415,708 635,288 
Other income, net4,796 2,729 10,584 6,667 
Net loss$(215,700)$(565,708)$(405,124)$(628,621)
(1) Other expenses include general and administrative expenses excluding compensation and stock-based compensation.

As of June 30, 2026 and December 31, 2025, substantially all of the Company’s long-lived assets are located in the United States.